

Jeannine S Mccune

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2775685/publications.pdf>

Version: 2024-02-01

135
papers

5,103
citations

87723

38
h-index

110170

64
g-index

136
all docs

136
docs citations

136
times ranked

6175
citing authors

#	ARTICLE	IF	CITATIONS
1	Adapting regulatory drug-drug interaction guidance to design clinical pharmacokinetic natural product-drug interaction studies: A NaPDI Center recommended approach. <i>Clinical and Translational Science</i> , 2022, 15, 322-329.	1.5	3
2	Pharmacometabonomic association of cyclophosphamide 4-hydroxylation in hematopoietic cell transplant recipients. <i>Clinical and Translational Science</i> , 2022, 15, 1215-1224.	1.5	6
3	Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 726-729.	1.3	1
4	Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning. <i>Journal of Proteome Research</i> , 2021, 20, 684-694.	1.8	6
5	Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach. <i>Pharmacological Reviews</i> , 2021, 73, 847-859.	7.1	8
6	Concepts and Applications of Information Theory to Immuno-Oncology. <i>Trends in Cancer</i> , 2021, 7, 335-346.	3.8	12
7	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	0.6	26
8	Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29203.	0.8	4
9	Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 657-663.	1.0	7
10	Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	2
11	Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 48-56.	2.0	5
12	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e235-e236.	2.0	0
13	Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 962-972.	2.9	19
14	A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1104-1112.	1.7	11
15	Environmental Exposures during Puberty: Window of Breast Cancer Risk and Epigenetic Damage. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 493.	1.2	21
16	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1070-1082.	5.1	169
17	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1890-1897.	2.0	19
18	Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach. <i>Natural Product Reports</i> , 2019, 36, 1196-1221.	5.2	72

#	ARTICLE	IF	CITATIONS
19	Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. <i>Blood</i> , 2019, 134, 211-215.	0.6	18
20	A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. , 2019, 201, 25-38.		65
21	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431.	2.0	14
22	Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (<i>Camellia</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 In Vivo Extrapolation. <i>Drug Metabolism and Disposition</i> , 2018, 46, 552-560.	1.7	22
23	Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1802-1807.	2.0	9
24	Rapid Advances in Immunotherapy to Treat Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 540-544.	2.3	64
25	Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. <i>International Journal of Hyperthermia</i> , 2018, 34, 284-291.	1.1	35
26	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Childrenâ€™s Oncology Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 2770-2777.	0.8	124
27	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018, 13, e0198389.	1.1	86
28	Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1041-1045.	1.7	20
29	Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Productâ€™Drug Interactions: A NaPDI Center Recommended Approach. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1046-1052.	1.7	19
30	Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)Ã¢â€šâ€šAn ACCRU Network study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 611-611.	0.8	32
31	Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 620-620.	0.6	0
32	Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 344-349.	0.5	15
33	Comparison of Metabolomics Approaches for Evaluating the Variability of Complex Botanical Preparations: Green Tea (<i>Camellia sinensis</i>) as a Case Study. <i>Journal of Natural Products</i> , 2017, 80, 1457-1466.	1.5	53
34	Development and Validation of a Novel Acute Myeloid Leukemiaâ€™Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017, 3, 1675.	3.4	125
35	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 461-470.	0.6	13
36	Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoietic Cell Transplant Recipients. <i>Journal of Proteome Research</i> , 2016, 15, 2802-2811.	1.8	23

#	ARTICLE	IF	CITATIONS
37	Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S406.	2.0	0
38	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <i>Blood</i> , 2016, 127, 1502-1508.	0.6	174
39	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1582-1587.	2.0	20
40	The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone. <i>Oncologist</i> , 2016, 21, 320-326.	1.9	59
41	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1915-1925.	2.0	130
42	Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study. <i>Lancet Haematology</i> , 2016, 3, e516-e525.	2.2	10
43	Prediction of intravenous busulfan clearance by endogenous plasma biomarkers using global pharmacometabolomics. <i>Metabolomics</i> , 2016, 12, 1.	1.4	17
44	Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. <i>Clinical Pharmacokinetics</i> , 2016, 55, 525-550.	1.6	42
45	Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. <i>Clinical Pharmacokinetics</i> , 2016, 55, 551-593.	1.6	32
46	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	0.6	18
47	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children's Oncology Group (COG) study. <i>Journal of Clinical Oncology</i> , 2016, 34, 10528-10528.	0.8	3
48	Pharmacogenetics of treatment response in patients with high-risk neuroblastoma: A Children's Oncology Group study. <i>Journal of Clinical Oncology</i> , 2016, 34, 10560-10560.	0.8	0
49	Developing and Using Therapeutics for Emerging Infections. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 346-351.	2.3	4
50	Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 85-96.	1.1	14
51	Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians. <i>Journal of Biomedical Informatics</i> , 2015, 55, 249-259.	2.5	27
52	Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 3738-3746.	0.4	76
53	Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 67-75.	1.1	13
54	Optimizing drug therapy in pediatric SCT: Focus on pharmacokinetics. <i>Bone Marrow Transplantation</i> , 2015, 50, 165-172.	1.3	13

#	ARTICLE	IF	CITATIONS
55	Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality. <i>Blood</i> , 2015, 126, 532-532.	0.6	6
56	Costs and resource utilization associated with skeletal related events in Medicare patients with prostate cancer metastatic to bones.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6612-6612.	0.8	2
57	Impact of skeletal-related events on survival in patients with prostate cancer metastatic to bones.. <i>Journal of Clinical Oncology</i> , 2015, 33, 223-223.	0.8	1
58	Abstract P4-08-01: Assessing the safety and feasibility of efficient hypothesis testing in patients with metastatic triple negative breast cancer. , 2015, , .		0
59	Predictive Performance of a Physiologically Based Pharmacokinetic Model of Busulfan in Children. <i>Pediatric Hematology and Oncology</i> , 2014, 31, 731-742.	0.3	21
60	Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization. <i>Clinical Cancer Research</i> , 2014, 20, 754-763.	3.2	112
61	Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM [®] model to optimize dosing. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 839-847.	0.8	16
62	Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: A mixed methods approach. <i>International Journal of Medical Informatics</i> , 2014, 83, 473-483.	1.6	71
63	Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated with Mycophenolate Mofetil. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1121-1129.	2.0	21
64	Recipient Pretransplant Inosine Monophosphate Dehydrogenase Activity in Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1544-1552.	2.0	7
65	A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 607-618.	1.1	9
66	Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1033-1039.	2.0	65
67	Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 991-1000.	1.1	14
68	Nonrelapse Mortality and Mycophenolic Acid Exposure in Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1159-1166.	2.0	29
69	Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 393-402.	1.0	40
70	Variation in Prescribing Patterns and Therapeutic Drug Monitoring of Intravenous Busulfan in Pediatric Hematopoietic Cell Transplant Recipients. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 264-275.	1.0	34
71	Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 621-626.	0.8	30
72	High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 711-7.	0.3	13

#	ARTICLE	IF	CITATIONS
73	Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 581-588.	1.3	38
74	A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration×Time Curve in Hematopoietic Cell Transplantation Recipients. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1654-1664.	1.0	17
75	Potential Contribution of Cytochrome P450 2B6 to Hepatic 4-Hydroxycyclophosphamide Formation In Vitro and In Vivo. <i>Drug Metabolism and Disposition</i> , 2012, 40, 54-63.	1.7	42
76	Aprepitant Pharmacokinetics and Assessing the Impact of Aprepitant on Cyclophosphamide Metabolism in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 586-594.	1.0	27
77	Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 265-272.	2.0	59
78	Colony-Stimulating Factor Use and Impact on Febrile Neutropenia Among Patients with Newly Diagnosed Breast, Colorectal, or Non-Small Cell Lung Cancer Who Were Receiving Chemotherapy. <i>Pharmacotherapy</i> , 2012, 32, 7-19.	1.2	14
79	Patterns of blood product use among patients with myelodysplastic syndrome. <i>Vox Sanguinis</i> , 2012, 102, 331-337.	0.7	12
80	A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 263-272.	1.1	17
81	Health Care Use and Primary Prophylaxis with Colony-Stimulating Factors. <i>Value in Health</i> , 2011, 14, 247-252.	0.1	7
82	Pharmacogenetics of Intravenous and Oral Busulfan in Hematopoietic Cell Transplant Recipients. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1429-1438.	1.0	37
83	A Pilot Study of Website Information Regarding Aromatase Inhibitors: Dietary Supplement Interactions. <i>Journal of Alternative and Complementary Medicine</i> , 2011, 17, 1043-1049.	2.1	8
84	Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. <i>Journal of Clinical Investigation</i> , 2010, 120, 2345-2354.	3.9	101
85	Development of a Population Pharmacokinetics-Based Sampling Schedule to Target Daily Intravenous Busulfan for Outpatient Clinic Administration. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1292-1300.	1.0	29
86	Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes. <i>Scientia Pharmaceutica</i> , 2010, 78, 473-481.	0.7	44
87	Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. <i>American Journal of Managed Care</i> , 2010, 16, 678-86.	0.8	36
88	Population Pharmacokinetics of Cyclophosphamide and Metabolites in Children With Neuroblastoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 88-102.	1.0	34
89	A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients. <i>Clinical Cancer Research</i> , 2009, 15, 5280-5287.	3.2	22
90	A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 391-401.	1.1	19

#	ARTICLE	IF	CITATIONS
91	Intracellular disposition of fludarabine triphosphate in human natural killer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 959-964.	1.1	7
92	Personalized Dosing of Cyclophosphamide in the Total Body Irradiationâ€“Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients With Hematologic Malignancy. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 615-622.	2.3	73
93	Busulfan in hematopoietic stem cell transplant setting. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 957-969.	1.5	89
94	Establishment of Long-Term Tolerance to SRBC in Dogs by Recombinant Canine CTLA4-Ig. <i>Transplantation</i> , 2009, 88, 317-322.	0.5	23
95	Low Toxicity and Mortality with Reversed-Order Conditioning (Cyclophosphamide Followed by) Tj ETQq1 1 0.784314 rgBT /Overlock 10 of a Prospective Clinical Trial.. <i>Blood</i> , 2009, 114, 1175-1175.	0.6	2
96	Imatinib inhibition of fludarabine uptake in T-lymphocytes. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 735-739.	1.1	15
97	Optimal Prevention of Seizures Induced by Highâ€“Dose Busulfan. <i>Pharmacotherapy</i> , 2008, 28, 1502-1510.	1.2	79
98	Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation. <i>Pharmacogenomics Journal</i> , 2008, 8, 248-255.	0.9	14
99	Fluconazole Coadministration Concurrent with Cyclophosphamide Conditioning May Reduce Regimen-Related Toxicity Postmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 760-764.	2.0	32
100	Cyclophosphamide following Targeted Oral Busulfan as Conditioning for Hematopoietic Cell Transplantation: Pharmacokinetics, Liver Toxicity, and Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 853-862.	2.0	89
101	Current Status of Cetuximab for the Treatment of Patients with Solid Tumors. <i>Annals of Pharmacotherapy</i> , 2006, 40, 241-250.	0.9	31
102	Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 573-584.	2.0	88
103	Pharmacokinetics of Oral Mycophenolate Mofetil in Dog: Bioavailability Studies and the Impact of Antibiotic Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1352-1354.	2.0	19
104	Cyclophosphamide disposition in an anephric child. <i>Pediatric Blood and Cancer</i> , 2006, 46, 99-104.	0.8	12
105	Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatographyâ€“mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 835, 105-113.	1.2	36
106	Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach. <i>Clinical Cancer Research</i> , 2006, 12, 4888-4898.	3.2	40
107	Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately High to Highly Emetogenic Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 270-276.	0.6	30
108	A highly sensitive high-performance liquid chromatographyâ€“mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 820, 243-250.	1.2	15

#	ARTICLE	IF	CITATIONS
109	Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 298-308.	2.3	31
110	The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. <i>Cancer</i> , 2005, 104, 2054-2062.	2.0	29
111	The absolute bioavailability of oral vinorelbine in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 578-584.	1.1	26
112	Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?. <i>Genetics in Medicine</i> , 2005, 7, 380-389.	1.1	62
113	CONTRIBUTION OF CYP3A5 TO HEPATIC AND RENAL IFOSFAMIDE N-DECHLOROETHYLATION. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1074-1081.	1.7	56
114	Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors. <i>Journal of Oncology Pharmacy Practice</i> , 2005, 11, 37-43.	0.5	8
115	Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. <i>Blood</i> , 2005, 106, 4381-4388.	0.6	69
116	A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 465-471.	2.0	78
117	A Phase I Trial Defining the Maximum Tolerated Systemic Exposure of Topotecan in Combination with Carboplatin and Etoposide in Extensive Stage Small Cell Lung Cancer. <i>Cancer Investigation</i> , 2005, 23, 511-519.	0.6	2
118	A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 495-505.	2.0	115
119	Potential of chemotherapy?herb interactions in adult cancer patients. <i>Supportive Care in Cancer</i> , 2004, 12, 454-462.	1.0	123
120	Influence of Age Upon Ifosfamide-Induced Nephrotoxicity. <i>Pediatric Blood and Cancer</i> , 2004, 42, 427-432.	0.8	23
121	Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. <i>Anti-Cancer Drugs</i> , 2004, 15, 453-459.	0.7	41
122	Topotecan Disposition in an Anephric Child. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 596-600.	0.3	11
123	Myalgias and arthralgias associated with paclitaxel. <i>Oncology</i> , 2003, 17, 271-7; discussion 281-2, 286-8.	0.4	20
124	The Effect of Cyclophosphamide with and without Dexamethasone on Cytochrome P450 3A4 and 2B6 in Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2002, 30, 814-822.	1.7	88
125	Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 167-173.	1.3	113
126	Pharmacological Considerations of Primary Alkylators. <i>Cancer Treatment and Research</i> , 2002, 112, 323-345.	0.2	4

#	ARTICLE	IF	CITATIONS
127	Lack of Gender Differences and Large Intrasubject Variability in Cytochrome P450 Activity Measured by Phenotyping with Dextromethorphan. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 723-731.	1.0	52
128	Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 373-379.	1.1	33
129	In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 356-366.	2.3	133
130	Granulocyte Colony-Stimulating Factor Use in Cancer Patients. <i>Annals of Pharmacotherapy</i> , 2000, 34, 851-857.	0.9	16
131	Plasma Concentration Monitoring of Busulfan. <i>Clinical Pharmacokinetics</i> , 2000, 39, 155-165.	1.6	137
132	Perception of Chemotherapy Side Effects Cancer versus Noncancer Patients. <i>Cancer Practice</i> , 1999, 7, 59-65.	0.8	161
133	Cancer Pain Survey. <i>Journal of Pain and Symptom Management</i> , 1998, 15, 275-284.	0.6	98
134	Appropriateness of maximum-dose guidelines for vincristine. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 1755-1758.	0.5	30
135	The essential research curriculum for doctor of pharmacy degree programs 2021. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	0.5	4